Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PNP | P00491 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.35 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.35 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | ALPL | P05186 | 1/20 | 0.33 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30431623 | 0.73 | PNP (0.40) | ALDH1A1PNPADORA3ADORA2AADORA1 | |
| SCHEMBL30089497 | 0.73 | — | — | |
| SCHEMBL30089575 | 0.72 | PARP1 (0.40) | ALDH1A1PNPDPP4GDAPDPK1 | |
| SCHEMBL41788 | 0.66 | PNP (0.50) | ALDH1A1PNPDPP4GDAPDPK1 | |
| SCHEMBL5277356 | 0.65 | PNP (0.45) | ALDH1A1PNPDPP4GDAPDPK1 | |
| SCHEMBL8886040 | 0.64 | PNP (0.49) | ALDH1A1PNPDPP4GDAPDPK1 | |
| SCHEMBL2983851 | 0.64 | PNP (0.49) | ALDH1A1PNPDPP4GDAPDPK1 | |
| SCHEMBL20867 | 0.64 | ATAD2 (0.53) | PNPDPP4GDAPDPK1ADORA3 | |
| SCHEMBL1843777 | 0.64 | PNP (0.49) | ALDH1A1PNPDPP4GDAPDPK1 | |
| SCHEMBL20579 | 0.64 | DPP4 (0.50) | ALDH1A1PNPDPP4GDAPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1430145-A4 | METHODS AND KITS FOR DETERMING A RISK TO DEVELOP CANCER, FOR EVALUATING AN EFFECTIVENESS AND DOSAGE OF CANCER THERAPY AND FOR CORRELATING BETWEEN AN ACTIVITY OF A DNA REPAIR ENZYME AND A CANCER | YEDA RES & DEV (IL) | 2006-08-16 | — | — | EP | claimed |
| EP-1430145-A2 | METHODS AND KITS FOR DETERMING A RISK TO DEVELOP CANCER, FOR EVALUATING AN EFFECTIVENESS AND DOSAGE OF CANCER THERAPY AND FOR CORRELATING BETWEEN AN ACTIVITY OF A DNA REPAIR ENZYME AND A CANCER | YEDA RESEARCH AND DEVELOPMENT COMPANY, LTD. (IL) | 2004-06-23 | — | — | EP | claimed |
| US-20040096863-A1 | Methods and kits for determining a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a dna repair enzyme and a cancer | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2004-05-20 | — | — | US | claimed |
| US-20030003454-A1 | Methods and kits for determining a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a DNA repair enzyme and a cancer | YEDA RESEARCH AND DEVELOPMENT CO. LTD. AT THE WEIZMANN INSTITUTE OF SCIENCE | 2003-01-02 | — | — | US | claimed |
| WO-2002076280-A2 | METHODS AND KITS FOR DETERMING A RISK TO DEVELOP CANCER, FOR EVALUATING AN EFFECTIVENESS AND DOSAGE OF CANCER THERAPY AND FOR CORRELATING BETWEEN AN ACTIVITY OF A DNA REPAIR ENZYME AND A CANCER | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2002-10-03 | — | — | WO | claimed |
| US-12523657-B2 | DNA repair blood test for predicting response of lung cancer patients to immunotherapy | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2026-01-13 | — | — | US | disclosed |
| EP-4655411-A2 | ENZYMATIC SYNTHESIS OF POLYNUCLEOTIDE PROBES | DNA Script (FR) | 2025-12-03 | — | — | EP | disclosed |
| US-20250305030-A1 | DNA ADDUCTOMICS BY MASS TAG PRELABELING | UNIV NORTHEASTERN (US) | 2025-10-02 | — | — | US | disclosed |
| US-12421628-B2 | Massively parallel enzymatic synthesis of nucleic acid strands | DNA SCRIPT (FR) | 2025-09-23 | — | — | US | disclosed |
| US-12359243-B2 | DNA adductomics by mass tag prelabeling | NORTHEASTERN UNIVERSITY (US) | 2025-07-15 | — | — | US | disclosed |
| US-20250215617-A1 | MASSIVELY PARALLEL ENZYMATIC SYNTHESIS OF NUCLEIC ACID STRANDS | DNA SCRIPT (FR) | 2025-07-03 | — | — | US | disclosed |
| US-20250180555-A1 | SINGLE-MOLECULE ANALYSIS OF NUCLEIC ACID BINDING PROTEINS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-06-05 | — | — | US | disclosed |
| EP-2308994-A1 | Methods for determining a risk to develop cancer | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2011-04-13 | — | — | EP | disclosed |
| US-7385051-B2 | Fluorescent N2,N3-etheno-purine (2′-deoxy) riboside derivatives and uses thereof | BAR-LLAN UNIVERSITY (IL) | 2008-06-10 | — | — | US | disclosed |
| EP-1430145-A4 | METHODS AND KITS FOR DETERMING A RISK TO DEVELOP CANCER, FOR EVALUATING AN EFFECTIVENESS AND DOSAGE OF CANCER THERAPY AND FOR CORRELATING BETWEEN AN ACTIVITY OF A DNA REPAIR ENZYME AND A CANCER | YEDA RES & DEV (IL) | 2006-08-16 | — | — | EP | disclosed |
| US-20060166248-A1 | Fluorescent N2, N3-etheno-purine (2'deoxy) riboside derivatives and uses thereof | BAR-ILAN UNIVERSITY (IL) | 2006-07-27 | — | — | US | disclosed |
| EP-1430145-A2 | METHODS AND KITS FOR DETERMING A RISK TO DEVELOP CANCER, FOR EVALUATING AN EFFECTIVENESS AND DOSAGE OF CANCER THERAPY AND FOR CORRELATING BETWEEN AN ACTIVITY OF A DNA REPAIR ENZYME AND A CANCER | YEDA RESEARCH AND DEVELOPMENT COMPANY, LTD. (IL) | 2004-06-23 | — | — | EP | disclosed |
| US-20040096863-A1 | Methods and kits for determining a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a dna repair enzyme and a cancer | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2004-05-20 | — | — | US | disclosed |
| US-20030003454-A1 | Methods and kits for determining a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a DNA repair enzyme and a cancer | YEDA RESEARCH AND DEVELOPMENT CO. LTD. AT THE WEIZMANN INSTITUTE OF SCIENCE | 2003-01-02 | — | — | US | disclosed |
| WO-2002076280-A2 | METHODS AND KITS FOR DETERMING A RISK TO DEVELOP CANCER, FOR EVALUATING AN EFFECTIVENESS AND DOSAGE OF CANCER THERAPY AND FOR CORRELATING BETWEEN AN ACTIVITY OF A DNA REPAIR ENZYME AND A CANCER | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166248-A1 | Fluorescent N2, N3-etheno-purine (2'deoxy) riboside derivatives and uses thereof | NUDT1, NT5C2, DUT | ALDH1A1 1811/4885PNP 15/4885DPP4 2606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.